SGLT-2 inhibitors were found to be more effective than sulfonylureas or DPP-4 inhibitors in lowering mean haemoglobin A1c levels, body mass index, and systolic blood pressure for a broad population of people with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.